Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562003 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00562003 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 26 participants.
The verdict
NCT00562003, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the maximally tolerated dose and spectrum of toxicities encountered with intraperitoneal delivery of a RGD modified conditionally replicative adenovirus (Ad5-Delta 24RGD) in patients with recurrent ovarian cancer. Secondary objectives : * To determine the biologic effects encountered with intraperitoneal delivery of Ad5-Delta 24RGD in patients with recurrent ovarian cancer cells * To determine immunologic response generated against Ad5-Delta 24RGD when administered intraperitoneally to patients with recurrent ovarian adenocarcinoma * To determine potential clinical activity of Ad5-Delta 24RGD when administered intraperitoneally to patients with recurrent ovarian adenocarcinoma
Interventions
- PROCEDURE Tenckhoff Catheter placement
- DRUG Ad5-delta24RGD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00562003
The ClinicalTrials.gov registry entry for NCT00562003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenckhoff Catheter placement is the first listed.
NCT00562003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00562003 about?
NCT00562003 is a clinical study titled "Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients". The primary purpose of this study is to determine the maximally tolerated dose and spectrum of toxicities encountered with intraperitoneal delivery of a RGD modified conditionally replicative adenovirus (Ad5-Delta 24RGD) in patients with recurrent ovarian cancer. Secondary objectives : * To determ...
What is the current status of trial NCT00562003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2007-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00562003?
The interventions under investigation include: Tenckhoff Catheter placement (PROCEDURE), Ad5-delta24RGD (DRUG).
Who is sponsoring clinical trial NCT00562003?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.